Meeting
2012 ASCO Annual Meeting
Results of a phase II trial of azacitidine (AZA) with or without epoetin beta (EPO) in lower-risk MDS.
Authors
Claude Gardin
Hematology, Hopital Avicenne APHP, University of Paris 13, Bobigny, France
Claude Gardin , Sylvain Thépot , Odile Beyne-Rauzy , Thomas Prébet , Sophie Park , Aspasia Stamatoulas , Agnes Guerci-Bresler , Stephane Cheze , Gerard Tertian , B Choufi , Laurence Legros , jean Noel Bastie , Jacques Delaunay , Eric Wattel , Francois Dreyfus , Norbert Vey , Simone Boehrer , Pierre Fenaux
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Other Leukemia, Myelodysplastic Syndromes, and Allotransplant
Clinical Trial Registration Number
01015352
Citation
J Clin Oncol 30, 2012 (suppl; abstr 6523)
DOI
10.1200/jco.2012.30.15_suppl.6523
Abstract #
6523
Poster Bd #
15
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)–naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial.
First Author: Amer Methqal Zeidan
Poster
2020 ASCO Virtual Scientific Program
Clinical benefit of luspatercept in patients (pts) with lower-risk MDS (LR-MDS) and high transfusion burden in the phase III MEDALIST study.
First Author: Amer Methqal Zeidan
Poster
2018 ASCO Annual Meeting
A phase 2, multicenter, open-label study of the safety and efficacy of luspatercept in subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis and anemia with or without RBC transfusion dependence.
First Author: Ruben A. Mesa
Poster
2024 ASCO Annual Meeting
Impact of pacritinib on symptoms in with thrombocytopenia and myelofibrosis who require red blood cell transfusion.
First Author: Stephen Oh